1401 studies found for:    Recruiting | cancer | United States, Texas
Show Display Options
Rank Status Study
21 Recruiting A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Neoplasms;   Peritoneal Neoplasms;   Fallopian Tube Neoplasms
Interventions: Drug: Trabectedin;   Drug: DOXIL;   Drug: Dexamethasone
22 Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
23 Recruiting Observation in Patients With Early-Stage Vulvar Cancer Following Surgery and/or Radiation Therapy
Conditions: Long-term Effects Secondary to Cancer Therapy in Adults;   Squamous Cell Carcinoma of the Vulva;   Stage I Vulvar Cancer;   Stage II Vulvar Cancer;   Stage III Vulvar Cancer
Interventions: Other: clinical observation;   Procedure: sentinel lymph node biopsy;   Procedure: therapeutic conventional surgery;   Procedure: therapeutic lymphadenectomy;   Radiation: selective external radiation therapy
24 Recruiting S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
Interventions: Drug: FOLFOX regimen;   Drug: docetaxel;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
25 Recruiting Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
Conditions: Ovarian Cancer;   Cancer of Ovary;   Cancer of the Ovary;   Ovary Neoplasms;   Primary Peritoneal Carcinoma
Intervention: Drug: Fenretinide/LXS + Ketoconazole
26 Recruiting Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer
Conditions: Cervical Cancer;   Endometrial Cancer;   Gastrointestinal Complications;   Perioperative/Postoperative Complications;   Radiation Toxicity;   Urinary Complications;   Urinary Tract Toxicity
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
27 Recruiting Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: docetaxel;   Drug: carboplatin;   Biological: trastuzumab;   Biological: pertuzumab;   Drug: goserelin acetate;   Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis;   Drug: aromatase inhibition therapy;   Other: quality-of-life assessment
28 Recruiting A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Condition: Carcinoma, Transitional Cell , Bladder Cancer, Bladder Tumors, Urinary Bladder Neoplasms
Intervention: Drug: MPDL3280A
29 Recruiting Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
Conditions: Lymphedema;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Procedure: Axillary Lymph Node Dissection;   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
30 Recruiting Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Conditions: Pancreatic Neoplasms;   Digestive System Neoplasms;   Neoplasms by Site;   Neoplasms;   Endocrine Gland Neoplasms;   Pancreatic Diseases;   Digestive System Diseases;   Endocrine System Diseases;   Gemcitabine;   Antimetabolites, Antineoplastic
Interventions: Drug: nab-Paclitaxel 125 mg/m2;   Drug: gemcitabine 1000 mg/m2
31 Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Distal Urethral Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Prostate Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Stage IV Bladder Cancer;   Stage IV Prostate Cancer;   Transitional Cell Carcinoma of the Bladder;   Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Other: placebo;   Biological: bevacizumab;   Other: laboratory biomarker analysis
32 Recruiting Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
Conditions: Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Paget Disease of the Breast;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: docosahexaenoic acid;   Other: placebo;   Other: laboratory biomarker analysis
33 Recruiting Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer
Interventions: Drug: cisplatin;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
34 Recruiting Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: fulvestrant;   Drug: anastrozole
35 Recruiting Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Conditions: Glioblastoma Multiforme;   Squamous Cell Carcinoma of Head and Neck;   Prostate Cancer;   Ewing's Osteosarcoma;   Chronic Lymphocytic Leukemia;   Neoplasm Metastasis
Intervention: Drug: CC-115
36 Recruiting Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Intraductal Papillary Mucinous Neoplasm of the Pancreas;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: erlotinib hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: capecitabine;   Drug: fluorouracil;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
37 Recruiting Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Conditions: Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Stage I Wilms Tumor;   Stage II Wilms Tumor;   Stage III Wilms Tumor;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
Interventions: Drug: doxorubicin hydrochloride;   Procedure: therapeutic conventional surgery;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: carboplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy
38 Recruiting Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
Conditions: Prostate Neoplasms;   Genital Neoplasms, Male;   Urogenital Neoplasms;   Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
39 Recruiting A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Conditions: Cancer;   Cataract;   Low Bone Mineral Density;   Osteopenia;   Osteoporosis;   Prostate Cancer
Interventions: Biological: Denosumab;   Biological: Placebo
40 Recruiting Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
Conditions: Metastatic Breast Cancer;   Locally Recurrent Breast Cancer
Interventions: Drug: Abraxane;   Drug: IG-001

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years